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A B S T R A C T
Objective: To analyze 48 cases the risk factors of vancomycin-resistant Enterococcus (VRE) infections, the
antibiotic costs after infection, and the survival conditions.
Design: 1:3 matched case-control study a medical center in the eastern Taiwan area. The case group,
patients with VRE bacterial strains detected at the sterile sites, and the control group were randomly
selected from invasive vancomycin-sensitive Enterococcus (VSE) infected patients at the nearest time
point by taking the occurrence time of each VRE infection case as the reference time. Fisher exact tests
were conducted in order to verify the existence of differences between the case and control groups;
survival analysis was applied to explore the prognoses of the VRE infection cases.
Results: Themortality rate of the invasive VRE infection cases was 64.6%, which is obviously higher than
that of the invasive VSE infection cases (39.4%); the fact of taking chemotherapy during a hospital stay as
well as the use of third-generation cephalosporin, glycopeptides, and medicines of the metronidazole
category before the infections, are the risk factors of future invasive VRE infections. Moreover, the
antibiotic costs after the infections of invasive VRE infection cases are much higher than those of the VSE
infection cases (the average daily cost is 3,433 new Taiwan dollars (NTD) vs. 1,742 NTD).
Conclusions: The history of receiving chemotherapy, the use of third-generation cephalosporin,
glycopeptides, and medicines of the metronidazole category before the infections are the risk factors
of VRE infections. The antibiotic costs after the infections of invasive VRE infection cases aremuch higher
than those of the VSE infection cases.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Vancomycin-resistant Enterococci (VRE) were ﬁrst identiﬁed in
19888 and have become a major nosocomial pathogen in Taiwan.
Taiwan Nosocomial Infections Surveillance (TNIS) shows that the
percentage of nosocomial Infections accounted for by VRE in ICUs
in medical centers increased from 3% in 2003 to 24% in 2011. The
study found cases of VRE infection crude mortality rate of 64% in
National Taiwan University Hospital from 1993 to 2000. It
demonstrates that hospital-acquired infections caused by VRE
increases not only mortality rates but also costs of treatment and
care. Nevertheless, there is no study on increased costs and little* Corresponding author at: No.701, Zhongyang Rd., Sec .3, Hualien City 97004,
Taiwan, ROC. Tel.: +886 3 856 5301x2277.
E-mail address: lyndon@gms.tcu.edu.tw (C.-I. Chu).
http://dx.doi.org/10.1016/j.ijid.2016.11.005
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).research on risk factors of VRE infections with large sample size in
Taiwan.
2. Methods
From a medical center in Hualien, researchers collected
bacterial culture data from 2007 to 2012. After all subjects under
18 years of age were excluded, cases and control groups were
selected according to set requirements under a 1:3 matched case-
control study.
The variables data, as required by this study, were collected by
reviewing the medical records and electronic medical records
maintained by the hospital. First, Fisher exact testswere conducted
in order to verify the existence of differences between the
categorical variables of the risk factors of the VRE infection cases
and those of VSE infection cases, as well as the existence of
differences between the continuous variables of nonparametricciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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explored through survival analysis. The statistical analysis all
p-values < 0.05 was considered statistically signiﬁcant.
In the case group, patientswith VRE bacterial strains detected at
the normally sterile sites were taken as the individual cases, and
the bacterial culture time was mainly taken as the infection time.
In the control group, the individual cases were collected by taking
the occurrence time of each VRE infection case as the reference
time in order to search for invasive VSE infected patients at the
nearest time point as the individual cases of the control group. The
selection was made randomly in the event that there were more
than two individual cases suitable for the control group.
3. The collected data included
3.1. Basic variables
They include age, gender, place of residence, infection location
(community, ward or intensive care unit (ICU)), medical care
related infections or not, hospital discharge status (mortality or
survival), and number of days of hospital stay.
3.2. Disease-related factors
The variables included the severity of illness (using APACHE
2 score to calculate the disease severity status), related risk factors
(including whether the patient had an operation two weeks before
the inspection; whether the patient had a malignant tumor, poor
renal function, chronic liver function disease, diabetes, organ
transplantation, hemodialysis, orHIV infection;whether the patient
used steroid or cancer chemotherapy, was incontinent, had
pressure sores or leucopenia during the current stay at hospital);
whether the patient had septicemia; and the types of antibiotics
used before the infection and the Carlson comorbidity index (CCI),
and invasive treatment items (48 hours before specimen collection,
or the time of collecting the specimens and the information, such as
whether a breathing apparatus, a central venous catheter indwell-
ing, urethral catheter indwelling, or tracheal tube indwelling was
used at the time or 48 hours before the time).1
3.3. Medical factors
The variables included antibiotic cost before VRE infection, VRE
treatment, and when the antibiotic treatment for VRE started (VRE
treatment refers to the use of quinupristin-dalfopristin, linezolid,
daptomycin, and tigecycline;2 and when the antibiotic treatment
for VRE started is the timeframe between testing of VRE infection
and the administration of antibiotic, which are within 24 hours
after bacterial culture, between 24 to 48 hours after bacterial
culture, andover 72 hours after bacterial culture, andno treatment).
3.4. Prognostic factors
The survival times of each individual case of the two groups
were analyzed using the Kaplan-Meier test.
3.5. Deﬁnitions of the variables of each category
The invasive VRE infection cases were deﬁned as the individual
cases where the VRE bacterial strains were detected in blood,
ascetic ﬂuid, intra-abdominal abscess, pleural ﬂuid, and joint ﬂuid.
Poor renal function was deﬁned as creatinine clearance <60mL/
min; and poor liver function was deﬁned when at least two of the
following itemsweremet: bilirubin concentrationwas>2.5 mg/dL;
the aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) exceeded more than two times the normal value; and liverdisease was diagnosed. Leucopenia was deﬁned as white blood cell
count being <500/mm3.3
To determine VRE, BD Phoenix AutomatedMicrobiology System
was used to test Enterococcus strains for Vancomycin minimum
inhibitory concentration (MIC). VRE was conﬁrmed when MIC
result was >32 ug/Ml.
The antibiotic treatment costs were calculated as follows: the
types, dosages, frequencies and usage days of all antibiotics used;
the types, dosages, and usage days of the antibiotics used before
and after the infection, respectively, by taking the infection days as
the tangent points; and then calculate the costs of antibiotics. The
usage cost data of each antibiotic was collected by taking the unit
price of each antibiotic, as stipulated by the National Health
Insurance Administration in 2013,4 as the standard in order to add
up the total usage costs of each antibiotic, in order to reduce the
cost differences caused by currency inﬂation and medicine cost
ﬂuctuations.
Cases of healthcare-associated infections (HAIs) were deter-
mined based on the 2009 revision of HAI Surveillance Deﬁnition of
Taiwan Center for Diseases Control (CDC).
4. Results
There were a total of 50 invasive VRE infection cases during
2007-2012. Excluding the two cases where the age was under
18 years old (0 and 2 years old, respectively), the study team
collected 48 cases for study. The control group collectionwasmade
according to the designed study method of 1:3, with 144 cases
selected as the control group. However, two cases were not
incorporated, as the related data of the two patients’ medical
records could not be retrieved in time. In the end, 48 invasive VRE
infection cases and 142 invasive VSE infection cases were collected
for analysis.
There were 31 males (accounting for 64.6% of the gender ratio)
and 17 females (35.4%) in the invasive VRE infection cases; and
87 males (61.3%) and 55 females (38.7%) in the control group,
which shows no statistically signiﬁcant difference (p = 0.682) in
gender between the two groups. Regarding the average age, that of
the case group was 60.5  18.2 (median: 59.5), and that of the
control group was 65.7  15 (median: 67), which shows no
statistically signiﬁcant difference (p = 0.078), although the age of
the VSE group was older according to the age medians of the two
groups.
In terms of infection occurrence location, the VRE cases mostly
occurred in ICUs with 24 people (accounting for 50%); thus, there
were 41 (28.9%) VSE cases occurring in the ICUs. Chi-square testing
found that the invasive VRE infection cases had a higher
probability of infection in ICUs than the VSE infection cases,
which reached the statistically signiﬁcant level (p = 0.027).
Regarding hospital discharge, there were 31 (64.6%) mortality
cases by the time of hospital discharge in the VRE infection cases,
and the number of VSE infection cases was 56 (39.4%). Chi-square
testing found that the mortality rate of the VER cases was higher
than that of the VSE cases, and reached a statistically signiﬁcant
level (p = 0.003).
We found 52.1% (n = 25) of VRE infection cases used respirators
when the infections occurred, which is signiﬁcantly higher than
the 30.3% (n = 43) of VSE infections cases (P = 0.0006). In addition,
regarding the aspect of central catheter use, the VRE cases had a
higher use rate of central venous catheters at 81.3% (n = 39), which
is also higher than the 62.7% (n = 89) of the VSE infection cases
(p = 0.018). With regard to having septic shock, the rate of the VRE
infection cases was 43.8% (n = 21), which shows a signiﬁcant
difference (p = 0.028) from the 26.8% (n = 38) of VSE infection
cases. Regarding the aspect of steroid use before the infection, the
VRE infection cases had a higher use rate of 43.8% (n = 21), which is
Table 1
Descriptive statistical analysis of data of the invasive VRE case group and the invasive VSE control group from a medical center in Hualien during 2007 - 2012
VRE VSE P-value
(n=48) (n=142)
Gender
Male 31(64.6) 87(61.3) 0.682
Female 17(35.4) 55(38.7)
Age 60.518.2
(59.5)
65.715.0
(67)
0.057
Infection location 0.027*
Community 5(10.4) 25(17.6)
Ordinary ward 19(39.6) 76(53.5)
ICU 24(50) 41(28.9)
Enterococcus species <0.0001*
E.faecium 46(95.8) 40(28.2)
E.faecalis 2(4.2) 102(71.8)
Infection part 0.026*
Blood 26(54.2) 102(71.8)
Ascitic ﬂuid 18(37.5) 30(21.1)
Pleural ﬂuid 3(6.5) 4(2.8)
Spinal ﬂuid 1(2.1) 0(0)
Other 6(4.2)
Medical care related infections 23(47.9) 62(43.7) 0.608
Operation 11(22.9) 43(30.3) 0.328
Malignant tumor 16(33.3) 52(36.6) 0.681
Poor renal function 10(20.8) 35(24.6) 0.591
Liver disease 20(41.7) 49(34.5) 0.373
Diabetes 9(18.8) 42(29.6) 0.143
Mechanical ventilation 25(52.1) 43(30.3) 0.0006*
Central line use 39(81.3) 89(62.7) 0.018*
Urinary catheter 31(64.6) 88(62.0) 0.746
Incontinence 35(72.9) 89(62.7) 0.198
Pressure sore 9(18.8) 25(17.6) 0.858
Leucopenia 5(10.4) 6(4.2) 0.112
Septic shock 21(43.8) 38(26.8) 0.028*
Using steroids 21(43.8) 35(24.6) 0.012*
Hemodialysis 10(20.8) 23(16.2) 0.464
CCI 1.461.53
(1.0)
1.711.70
(1.0)
0.401
APACHE2 17.86.8
(16.0)
17.07.2
(16.0)
0.453
Total length of stay, median 55.447.7
(46)
3834
(25)
0.009*
Hospital stay days after infection 32.534.3
(21.5)
24.225.9
(15.5)
0.082
Hospital discharge status
Mortality 31(64.6) 56(39.4) 0.003*
Survival 17(35.4) 86(60.6)
Note: * p<0.05; the () in the category variable is the percentage; data presented as continuous variables are the average standard deviation (median). VRE: vancomycin-
resistant Enterococcus; VSE: vancomycin sensitive Enterococcus; ICU: intensive care unit; CCI: Charlson comorbidity index; APACHE 2: acute physiological and chronic health
evaluation 2.
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statistically signiﬁcant level (p = 0.012). Regarding the CCI index
and APACHE2 score, no signiﬁcant difference was found between
the data of the two groups after relevant testing (as shown in
Table 1).
With regard to antibiotic usage types before infection, it was
found that the average types of antibiotics used before the
infection by the VRE infection cases were 4.2  2.7 types (the
median was four kinds), while those by the VSE infection cases were
2.0  2.1 types (themedianwas one kind), which shows themore the
types of antibiotics are used, the bigger the chance of VRE infection
(p > 0.0001).
In terms of antibiotic usage costs during a hospital stay, the
average daily antibiotic usage cost of VRE infected patients during
their stay in the hospital was 2,666  2,077.9 new Taiwan dollars
(NTD) (median: 2,183.3 NTD), and that of VSE infected patients was
1,504  1,398 NTD (median: 1,216.3 NTD), showing that antibiotic
costs during a hospital stay, in the event that the patient is infected
with drug-resistant Enterococcus, are signiﬁcantly higher than those
of the non-drug-resistant Enterococcus cases (p < 0.0001). The sameresult was found from a comparison of antibiotic usage costs after an
infection. The average daily antibiotics usage cost of the VRE cases
after an infection was 3,433  2,966 NTD (median: 2,984.6 NTD),
while that of the VSE infection caseswas 1,742  1,611 NTD (median:
1425.2 NTD). p < 0.0001 was obtained upon testing the data of the
two groups, and reacheed a statistically signiﬁcant level (as shown in
Table 2).
Survival was analyzed using a Kaplan-Meier curve on the
invasive VRE infection cases and VSE infection cases. The average
survival days of the VRE cases was 52 days, while that of VSE
infection cases was 61 days, whichwas not signiﬁcant (as shown in
Fig. 1), and had an overall test result of p = 0.246.
Among the 190 patients in the collected invasive Enterococcus
infection cases, 103 (54.2%) survived and 87 (45.8%) did not. Cox
regression analysis was performed on the data of the two groups,
and the p-value of the overall model was tested to be lower than
0.001, indicating that the overall Cox regression model was
signiﬁcant. The APACHE2 score was higher when the patient was
found to have diabetes, leucopenia, or using the 4th-generation
cephalosporin; glycopeptides and carbapenem before an infection
Table 2
Descriptive statistical analysis of related antibiotic usage status and costs of the invasive VRE case group and the invasive VSE control group from amedical center in Hualien
during 2007 – 2012
VRE VSE P-value
(n=48) (n=142)
Types of antibiotics used before infection 4.22.7
(4)
2.02.1
(1)
<0.0001*
Antibiotic types used after infection 4.32.7
(4.5)
3.22.3
(3)
0.006*
Average daily antibiotic cost during the hospital stay 2666.12077.9
(2183.3)
1503.71397.9
(1216.3)
<0.0001*
Average daily antibiotic cost before infection 1589.91458.5
(1136.6)
902.91275.8
(472.4)
<0.0001*
Average daily antibiotic cost after infection 3433.32965.5
(2984.6)
1742.11611.6
(1425.2)
<0.0001*
Types of antibiotics used before infection
Aminoglycosides 22(45.8) 9(6.3) 0.611
Antifungals 21(43.8) 13(9.2) 0.058
1st-generation Cephalosporins 43(89.6) 11(7.7) 0.315
2nd-generation Cephalosporins 22(45.8) 5(3.5) 0.375
3rd-generation Cephalosporins 35(72.9) 20(14.1) 0.026*
4th-generation Cephalosporins 4(8.3) 4(2.8) 0.115
Glycopeptides 12(25) 17(12.0) <0.0001*
Glycylcyclines 5(10.4) 7(4.9) 0.013*
Macrolides 4(8.3) 2(1.4) 0.645
Oxazolidione 0(0) 2(1.4) 0.063
Penicillins 32(72.9) 25(17.6) <0.0001*
Quinolones 25(52.1) 21(14.8) <0.0001*
Sulfonamides 3(6.3) 4(2.8) 0.049*
Tetracyclines 0(0) 2(1.4) 0.063
Colistin 5(10.4) 4(2.8) 0.235
Metronidazole 12(25) 18(12.7) <0.0001*
Carbapenem 36(75) 28(19.7) <0.0001*
beta-lactamase Inhibitors 5(10.4) 10(7.0) 0.001*
Note:* p<0.05; the () in the category variable is the percentage; data presented as continuous variables are the average standard deviation (median). VRE: vancomycin-
resistant Enterococcus; VSE: vancomycin sensitive Enterococcus.[(Fig._1)TD$FIG]
Fig. 1. Survival analysis of the invasive VRE infection case group and of the control group of invasive VSE infection cases from a medical center in Hualien during 2007 –
2012. Note: VRE: vancomycin-resistant Enterococcus.
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prognosis. However, the drug–resistant or non-drug–resistant
nature of the bacterial strain infected does not constitute a risk
factor affecting the prognosis. (p = 0.45) (Table 3).The risk factors of VRE infections were explored by logistic
regression analysis, where the variables that may affect the drug-
resistant factors were placed into the model (gender, age, infection
occurrence location, nosocomial infection or not, use of a central
Table 3
Survival and mortality predictor data analysis of the invasive Enterococcus infection cases from a medical center in Hualien during 2007 - 2012
Survival Mortality HR P-value
(n=103) (n=87) (95%CI)
Gender 1.0(0.56-1.82) 0.984
Male 42(40.8) 30(34.5)
Female 61(59.2) 57(65.5)
Age 63.516.3
(66)
65.515.6
(66)
1.0(0.98-1.03) 0.597
Infection location 0.236
ICU 18(17.5) 47(54) Reference
Ordinary ward 67(65) 28(32.2) 0.4(0.17-1.18) 0.103
Community 18(17.5) 12(13.8) 0.64(0.27-1.48) 0.295
Bacterial strain
E.faecium 34(33) 52(59.8) Reference
E.faecalis 69(67) 35(40.2) 0.8(0.36-1.66) 0.511
Medical care related infections 41(39.8) 44(50.6) 0.7(0.34-1.28) 0.218
Operation 30(29.1) 24(27.6) 1.5(0.74-3.04) 0.262
Malignant tumor 37(35.9) 31(35.6) 1.0(0.46-2.16) 1.000
Poor renal function 22(21.4) 23(26.4) 0.9(0.44-1.95) 0.835
Liver disease 35(34.0) 34(39.1) 1.6(0.76-3.30) 0.220
Diabetes 31(30.1) 20(23.0) 0.3(0.15-0.61) 0.001*
Mechanical ventilation 22(21.4) 46(52.9) 0.8(0.37-1.88) 0.664
Central line use 54(52.4) 74(85.1) 1.8(0.77-4.11) 0.179
Urinary catheter 56(54.4) 63(72.4) 0.6(0.22-1.58) 0.290
Chemotherapy 6(5.8) 6(6.9) 0.5(0.10-2.21) 0.335
Incontinence 53(51.5) 71(81.6) 1.9(0.72-5.06) 0.190
Pressure sore 15(14.6) 19(21.8) 1.1(0.54-2.33) 0.768
Leucopenia 5(4.9) 6(6.9) 3.6(1.92-6.70) 0.000*
Septic shock 11(10.7) 48(55.2) 3.0(0.76-11.9) 0.116
Using steroids 20(19.4) 36(41.4) 1.9(0.91-3.80) 0.091
Hemodialysis 10(9.7) 23(26.4) 1.5(0.69-3.32) 0.307
CCI 1.61.7
(1)
1.71.6
(1)
1.1(0.84-1.34) 0.603
APACHE2 14.96.2
(15)
19.97.1
(18)
1.1(1.01-1.10) 0.022*
VRE 17(16.5) 31(35.6) 0.8(0.38-1.53) 0.450
Types of antibiotics used before infection
Aminoglycosides 19(18.4) 12(13.8) 0.8(0.31-1.96) 0.603
Antifungals 11(10.7) 23(26.4) 0.9(0.37-2.04) 0.754
1st-generation Cephalosporins 36(35) 18(20.7) 0.7(0.33-1.34) 0.257
2nd-generation Cephalosporins 15(14.6) 12(13.8) 0.7(0.27-2.00) 0.547
3rd-generation Cephalosporins 24(23.3) 31(35.6) 0.9(0.42-1.83) 0.730
4th-generation Cephalosporins 2(1.9) 6(6.9) 0.2(0.04-0.83) 0.027*
Glycopeptides 11(10.7) 18(20.7) 0.4(0.14-0.92) 0.033*
Glycylcyclines 3(2.9) 9(10.3) 3.3(0.86-12.92) 0.082
Macrolides 2(1.9) 4(4.6) 3.6(0.89-14.64) 0.073
Oxazolidinone 0(0) 2(2.3) 0.8(0.05-12.00) 0.857
Penicillins 23(22.3) 34(39.1) 1.0(0.50-1.99) 0.985
Quinolones 17(16.5) 29(33.3) 0.9(0.45-1.71) 0.700
Sulfonamides 4(3.9) 3(3.4) 1.4(0.25-7.72) 0.705
Tetracyclines 1(1) 1(1.1) 1.5(0.14-16.92) 0.727
Colistin 3(2.9) 6(6.9) 0.6(0.14-2.14) 0.391
Metronidazole 10(9.7) 20(23) 1.8(0.78-4.02) 0.174
Carbapenem 28(27.2) 36(41.4) 0.3(0.13-0.61) 0.001*
betalactamine 6(5.8) 9(10.3) 1.0(0.31-2.96) 0.947
Note: * p<0.05; the () in the category variable is the percentage; data presented as continuous variables are the average standard deviation (median). VRE: vancomycin-
resistant Enterococcus; VSE: vancomycin sensitive Enterococcus; ICU: intensive care unit; CCI: Charlson comorbidity index; APACHE 2: acute physiological and chronic health
evaluation 2. HR: hazard ratio.
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chemotherapy or not during the hospital stay, being diagnosed as
having septic shock or not, previous use of steroids, usage of 3rd-
generation cephalosporins, glycopeptides, glycylcyclines, penicil-
lins, quinolones, metronidazole, and carbapenem before the
infection). The R2 of the overall model was 0.283. The test result
of overall ﬁtness was p < 0.001, which reached the statistically
signiﬁcant level (as shown in Table 4).
Our results show that the use of 3rd-generation cephalosporins,
glycopeptides, and metronidazole-category medicines before the
infection of a patient who had cancer chemotherapy during a
hospital stay could effectively predict and explain the presence of
VRE. The odds ratio of patients infected with the vancomycin-
resistant enterococci who received chemotherapy was 6.3,
p = 0.042, while that of patients who received third-generationcephalosporin-category medicines before infection was 2.7,
p = 0.040; 4.2, p = 0.013 for those receiving glycopeptide-category
medicines; and 4.0, p = 0.014 for those receivingmetronidazole (as
shown in Table 4).
The factors inﬂuencing survival of VRE infection cases were
analyzed using Cox regression. After gender, age, CCI, and
APACHE2 score were adjusted, the overall model was p = 0.001,
showing a signiﬁcant overall Cox regression model. It was found
from the data that the risk of mortality in cases not receiving VRE
antibiotic treatment was 5.2 times that in cases receiving
treatment, which reached a statistically signiﬁcant level
(p < 0.0001). Moreover, each one-point increase in the APACHE2
score caused the risk of mortality to increase by 1.1 times, which
reached a statistically signiﬁcant level (p = 0.047) (as shown in
Table 5).
Table 4
Logistic regression model analysis of risk factors affecting drug resistance
VRE VSE Regression Test Analysis
(n =48) (n=142) OR(95%CI) P-value
Gender
Male 31(64.6) 87(61.3) Reference
Female 17(35.4) 55(38.7) 1.2(0.48-2.82) 0.734
Age 60.518.2
(59.5)
65.715.0
(67)
1.0(0.95-1.0) 0.195
Infection location
ICU 24(50) 41(28.9) Reference
Ordinary ward 19(39.6) 76(53.5) 0.8(0.23-2.86) 0.744
Community 5(10.4) 25(17.6) 3.0(0.61-14.2) 0.177
Medical care related infections 23(47.9) 62(43.7) 0.6(0.22-1.50) 0.258
Mechanical ventilation 25(52.1) 43(30.3) 2.2(0.62-7.60) 0.229
Central line use 39(81.3) 89(62.7) 1.2(0.39-3.62) 0.769
Chemotherapy 6(12.5) 6(4.2) 6.3(1.10-37.0) 0.042*
Septic shock 21(43.8) 38(26.8) 1.3(0.49-3.50) 0.592
Using steroids 21(43.8) 35(24.6) 0.6(0.19-1.81) 0.359
CCI 1.461.53
(1.0)
1.711.70
(1.0)
0.8(0.60-1.10) 0.174
APACHE2 17.86.8
(16.0)
17.07.2
(16.0)
1.0(0.91-1.05) 0.503
Types of antibiotics used before infection
3rd-generation Cephalosporins 35(72.9) 20(14.1) 2.7(1.04-7.14) 0.040*
Glycopeptides 12(25) 17(12) 4.2(1.36-12.91) 0.013*
Glycylcyclines 5(10.4) 7(4.9) 0.6(0.12-2.80) 0.492
Penicillins 32(72.9) 25(17.6) 2.5(0.93-6.69) 0.069
Quinolones 25(52.1) 21(14.8) 2.0(0.77-5.44) 0.150
Metronidazole 12(25) 18(12.7) 4.0(1.32-11.96) 0.014*
Carbapenem 36(75) 28(19.7) 2.4(0.92-6.30) 0.075
Note: data presented as continuous variables are the average standard deviation (median); the () in the category variable is the percentage; *p<0.05; CI = conﬁdence interval;
OR =odds ratio. VRE: vancomycin-resistant Enterococcus; VSE: vancomycin sensitive Enterococcus; ICU: intensive care unit; CCI: Charlson comorbidity index; APACHE 2: acute
physiological and chronic health evaluation 2.
Table 5
Analysis of the factors of invasive VRE infection cases affecting survival using Cox regression
Survival Mortality Test Analysis
(n =17) (n=31) HR(95%CI) P-value
Gender 1.7(0.76-3.94) 0.189
Male 11(64.7) 20(64.5)
Female 6(35.3) 11(35.5)
Age 5618.2
(52)
6318
(61)
1.0(0.99-1.03) 0.493
CCI 1.21.5
(0)
1.61.6
(1)
1.0 (0.78-1.31) 0.954
APACHE2 15.86.6
(15)
18.96.7
(18)
1.1 (1.00-1.13) 0.047*
VRE treatment Treated 14(82.4) 22(71) Reference
Not treated 3(17.6) 9(29) 5.2(2.08-12.90) <0.0001*
Note:* p<0.05; the () in the category variable is the percentage; data presented as continuous variables are the average standard deviation (median). VRE: vancomycin-
resistant Enterococcus; VSE: vancomycin sensitive Enterococcus; CCI: charlson comorbidity index; APACHE 2: acute physiological and chronic health evaluation 2.
H.-L. Jiang et al. / International Journal of Infectious Diseases 54 (2017) 18–24 23In addition, exploration of the inﬂuence of the early use of
related antibiotic treatment on the survival of VRE infection cases
found that, after Kaplan-Meier testing, there was no signiﬁcant
difference (p = 0.752) in the adoption of related early antibiotic
treatment on survival days (Table 6).Table 6
Inﬂuence of the treatment time of VRE infection cases on survival
Survival Mortality
(n=14) (n=22) P-value
Treatment time 0.752
Treatment within 24 hours 2(14.3) 8(36.4)
Treatment within 24-48 hours 3(21.4) 1(4.5)
Treatment after 72 hours 9(64.3) 13(59.1)
Note: VRE: vancomycin-resistant Enterococcus.5. Discussion
Invasive VRE infection does cause increased mortality, and
hospitalization costs should not be underestimated. The risk factor
of VRE infection is a history of receiving chemotherapy (p = 0.042)
(Table 4) before an infection after controlling for age, gender, and
disease severity. It is therefore suggested that active screening in
the future should be started in oncologywards, as the risk of patient
mortality could be effectively reduced if the VRE colonization could
be conﬁrmed early and related isolation and protection measures
were immediately taken to reduce the invasive infection. Regarding
the bacteremia data, the crude mortality rate was 73.1%, indicating
that the mortality rate of bacteremia would be higher than other
invasive infections, which is in accord with studies by the National
Taiwan University Hospital in 20015 and Chiayi Chang Gung
Memorial Hospital in 2010.6
H.-L. Jiang et al. / International Journal of Infectious Diseases 54 (2017) 18–2424After age, gender, and disease severity were controlled, we
found that the use of 3rd-generation cephalosporins, glycopeptides,
and metronidazole-category medicines before the infection had a
higher correlation with VRE infection (p < 0.05)(Table 4), which is
similar to other studies (Dai et al., 2010).6 Many people think the
early use of the correct antibiotics for treatment can increase
survival rate. The lack of an effect of an early antibiotic treatment
could be related to the relatively low number of patients evaluated
in the study. According to this study, most antibiotic treatments
start after 72 hours, accounting for 64.3%, while those starting
within 24 hours account for 14.3%. However, Kaplan-Meier
analysis demonstrated that the adoption of early antibiotic
treatment did not signiﬁcantly affect patients prognosis
(p = 0.752) (Table 6), which is consistent with the study results
of Han et al. in 2009.7 In addition to this, we also found that for
survival analyzed on the invasive VRE infection cases and VSE
infection cases, which was not signiﬁcant (as shown in Fig. 1), the
main reasonmay be the small number of study samples. Therefore,
although the number of survival days of the VRE cases was
signiﬁcantly lower than that for the VSE infection cases, it did not
reach the statistically signiﬁcant level.
This study analyzed the risk factors of infection, prognosis
status, and antibiotic usage costs by taking invasive VRE infection
cases as the main object of study, and is the ﬁrst in Taiwan to
conduct related studies on the antibiotic costs of invasive VRE
infections. In this study, the invasive VRE infections weremainly of
E.faecium, accounting for 95.8% (Table 1), which is much higher
than the invasive E.faecium infection rate (42.9%) found in the ﬁve
year study by Chiayi Chang GungMemorial Hospital,6 but closer to
the 100% rate found by the National Taiwan University Hospital
(Dai et al., 2010).6
Our study was limited by the fact that it was a retrospective
study of medical records, thus some deviations in datamight occur
in the event that some situations were not noted on the medical
records. Moreover, since the data under study belong to the same
hospital, and the number of samples is small, the representative-
ness of the sample would be affected.Currently, there is no standard treatment for VRE infection. A
prospective randomized placebo-controlled trial should be
designed to determine the optimal antibiotic choice to improve
patient survival and outcome.
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